Articoli correlati a Hematopoietic Growth Factors in Oncology: 157

Hematopoietic Growth Factors in Oncology: 157 - Rilegato

 
9781441970725: Hematopoietic Growth Factors in Oncology: 157
Vedi tutte le copie di questo ISBN:
 
 

Progress in the treatment of cancer over the past two decades has been rapid with many new and novel therapeutic modalities arriving at an unprecedented pace. Overall cancer mortality rates have actually begun to fall in parallel with progress in the diagnosis and treatment of malignant disease. Despite our advances in the understanding of the biology and molecular genetics of cancer, as well as the availability of an increasing array of effective therapies, cancer treatment today and for the foreseeable future will include the traditional modalities of surgery, radiation therapy and chemotherapy. Myelosuppressive agents with their potential hematopoietic toxicities remain the mainstay of systemic treatment for both metastatic and early stage cancer. The complications of cancer chemotherapy have serious impact on a patient’s well being and overall quality of life. Fortunately, advances in cancer treatment have been accompanied by equally impressive progress in the availability of a wide array of supportive care modalities which have greatly enhanced the ability of oncologists to minimize the impact of cancer and its treatment on patient quality of life as well improve delivery of potentially curative cancer treatment.

Despite the increasing complexity of modern cancer treatment, it is the obligation of the oncologist as well as the entire cancer care team to be certain that cancer patients receive the optimal supportive care available for their disease and its treatment. Among the most serious and potentially life threatening toxicities of cancer treatment are the hematologic toxicities accompanying myelosuppression including anemia and associated asthenia and fatigue, neutropenia and fever associated with infection in the immunocompromised patient and thrombocytopenia and accompanying risk of bleeding. Special supportive care needs arise in the very elderly care patient that may tax the ability of even the most skilled clinician. Despite the considerable progress that has been made with more effective and safer treatment strategies, myelosuppressive chemotherapy will remain the mainstay of systemic treatment for cancer for the foreseeable future. While considerable progress has occurred, better methods and broader application of supportive care measures are needed to reduce the symptomatic effects of cancer and the associated toxicities associated with cancer treatment.

No area of cancer supportive care better illustrates the progress that has resulted from advances in our understanding of cellular and molecular biology, genetic engineering and the development of more effective yet often more toxic cancer treatments than that of the hematopoietic growth factors. This volume will review and integrate the major advances in our understanding of the underlying molecular biology and pharmacology of these agents along with the results of well designed and executed randomized controlled trials of the erythroid stimulating agents, the myeloid growth factors and the new thrombopoietic agents each addressing a major threat associated with bone marrow suppression accompanying cancer treatment. The current clinical utilization of these agents is based on numerous randomized controlled trials and meta-analyses along with evidence-based clinical practice guidelines developed by professional societies guiding their appropriate and cost-effective use in clinical care.

Le informazioni nella sezione "Riassunto" possono far riferimento a edizioni diverse di questo titolo.

Contenuti:
Introduction to the Hematopoietic Growth Factors.- Early-Acting Hematopoietic Growth Factors: Biology and Clinical Experience.- Granulocyte Colony-Stimulating Factors.- Erythropoietic-Stimulating Agents.- Thrombopoietin Factors.- Cyclic and Chronic Neutropenia.- The Myeloid Growth Factors.- Meta-analyses of Randomized Controlled Trials of Granulocyte Colony-Stimulating Factor Prophylaxis in Adult Cancer Patients Receiving Chemotherapy.- Summary and Comparison of Myeloid Growth Factor Guidelines In Patients Receiving Cancer Chemotherapy.- Granulocyte Colony-Stimulating Factors and Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome.- Do Erythropoietic Stimulating Agents Relieve Fatigue? A Review of Review.- Randomized Controlled Trials of the Erythroid-Stimulating Agents in Cancer Patients.- Ten Years of Meta-Analyses on Erythropoiesis-Stimulating Agents in Cancer Patients.- Clinical Practice Guidelines for the Use of Erythroid-Stimulating Agents: ASCO, EORTC, NCCN.- Thrombocytopenia and Platelet Transfusions in Patients With Cancer.- Romiplostim.- Clinical Trials of the Thrombopoietic Mimetic Agents: ELTROMBOPAG.- The Hematopoietic Growth Factors in Acute Leukemia: US Perspective.- The Hematopoietic Growth Factors in Acute Leukemia: A European Perspective.- The Hematopoietic Growth Factors in the Myelodysplastic Syndromes.- The Hematopoietic Growth Factors in Older Cancer Patients.- The Economics of the Hematopoietic Growth Factors
Dalla quarta di copertina:
No area of cancer supportive care better illustrates the advances in our understanding of cellular and molecular biology, genetic engineering and the development of more effective yet often more toxic cancer treatments than that of hematopoietic growth factors. Myelosuppressive agents, with their potential hematopoietic toxicities, remain the mainstay of systemic treatment for both metastatic and early stage cancer. Hematopoietic Growth Factors in Oncology reviews and integrates the major advances in our understanding of the underlying molecular biology and pharmacology of these agents along with the results of well designed and executed randomized controlled trials of the erythroid stimulating agents, the myeloid growth factors and the new thrombopoietic agents, each addressing a major threat associated with bone marrow suppression accompanying cancer treatment. "Hematopoietic growth factors have revolutionized the treatment of patients with a spectrum of cancers and benign bone marrow disorders. This text addresses the mechanism of action and clinical impact of these cytokines. Leading investigators in the field provide and update of current state of knowledge and future challenges." – Steven T. Rosen, M.D. Series Editor

Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.

Spese di spedizione: EUR 4,78
Da: Regno Unito a: U.S.A.

Destinazione, tempi e costi

Aggiungere al carrello

Altre edizioni note dello stesso titolo

9781461427285: Hematopoietic Growth Factors in Oncology: 157

Edizione in evidenza

ISBN 10:  ISBN 13:  9781461427285
Casa editrice: Springer, 2012
Brossura

I migliori risultati di ricerca su AbeBooks

Foto dell'editore

Lyman, Gary
Editore: Springer (2010)
ISBN 10: 144197072X ISBN 13: 9781441970725
Nuovo Rilegato Quantità: 1
Da:
Bright Study Books
(London, Regno Unito)
Valutazione libreria

Descrizione libro Condizione: New. Book is brand new and shrink wrapped. Codice articolo 4pal131x

Informazioni sul venditore | Contatta il venditore

Compra nuovo
EUR 39,03
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 4,78
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi
Foto dell'editore

0
Editore: Springer (2010)
ISBN 10: 144197072X ISBN 13: 9781441970725
Nuovo Rilegato Quantità: 1
Da:
Basi6 International
(Irving, TX, U.S.A.)
Valutazione libreria

Descrizione libro Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Codice articolo ABEOCT23-354923

Informazioni sul venditore | Contatta il venditore

Compra nuovo
EUR 136,01
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
In U.S.A.
Destinazione, tempi e costi
Immagini fornite dal venditore

Editore: Springer (2010)
ISBN 10: 144197072X ISBN 13: 9781441970725
Nuovo Rilegato Quantità: 10
Da:
booksXpress
(Bayonne, NJ, U.S.A.)
Valutazione libreria

Descrizione libro Hardcover. Condizione: new. Codice articolo 9781441970725

Informazioni sul venditore | Contatta il venditore

Compra nuovo
EUR 204,74
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
In U.S.A.
Destinazione, tempi e costi
Foto dell'editore

Editore: Springer (2010)
ISBN 10: 144197072X ISBN 13: 9781441970725
Nuovo Rilegato Quantità: > 20
Da:
Lucky's Textbooks
(Dallas, TX, U.S.A.)
Valutazione libreria

Descrizione libro Condizione: New. Codice articolo ABLIING23Mar2411530297239

Informazioni sul venditore | Contatta il venditore

Compra nuovo
EUR 219,51
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 3,69
In U.S.A.
Destinazione, tempi e costi
Immagini fornite dal venditore

Lyman, Gary H.|Dale, David C.
Editore: Springer US (2010)
ISBN 10: 144197072X ISBN 13: 9781441970725
Nuovo Rilegato Quantità: > 20
Print on Demand
Da:
moluna
(Greven, Germania)
Valutazione libreria

Descrizione libro Gebunden. Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Illustrates the progress resulted from advances in our understanding of cellular and molecular biology, genetic engineering and the development of more effective yet often more toxic cancer treatments than that of the hematopoietic growth factorsReviews and. Codice articolo 4176232

Informazioni sul venditore | Contatta il venditore

Compra nuovo
EUR 175,51
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 48,99
Da: Germania a: U.S.A.
Destinazione, tempi e costi
Immagini fornite dal venditore

David C. Dale
Editore: Springer US Nov 2010 (2010)
ISBN 10: 144197072X ISBN 13: 9781441970725
Nuovo Rilegato Quantità: 2
Print on Demand
Da:
BuchWeltWeit Ludwig Meier e.K.
(Bergisch Gladbach, Germania)
Valutazione libreria

Descrizione libro Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Progress in the treatment of cancer over the past two decades has been rapid with many new and novel therapeutic modalities arriving at an unprecedented pace. Overall cancer mortality rates have actually begun to fall in parallel with progress in the diagnosis and treatment of malignant disease. Despite our advances in the understanding of the biology and molecular genetics of cancer, as well as the availability of an increasing array of effective therapies, cancer treatment today and for the foreseeable future will include the traditional modalities of surgery, radiation therapy and chemotherapy. Myelosuppressive agents with their potential hematopoietic toxicities remain the mainstay of systemic treatment for both metastatic and early stage cancer. The complications of cancer chemotherapy have serious impact on a patient's well being and overall quality of life. Fortunately, advances in cancer treatment have been accompanied by equally impressive progress in the availability of a wide array of supportive care modalities which have greatly enhanced the ability of oncologists to minimize the impact of cancer and its treatment on patient quality of life as well improve delivery of potentially curative cancer treatment. Despite the increasing complexity of modern cancer treatment, it is the obligation of the oncologist as well as the entire cancer care team to be certain that cancer patients receive the optimal supportive care available for their disease and its treatment. Among the most serious and potentially life threatening toxicities of cancer treatment are the hematologic toxicities accompanying myelosuppression including anemia and associated asthenia and fatigue, neutropenia and fever associated with infection in the immunocompromised patient and thrombocytopenia and accompanying risk of bleeding. Special supportive care needs arise in the very elderly care patient that may tax the ability of even the most skilled clinician. Despite the considerable progress that has been made with more effective and safer treatment strategies, myelosuppressive chemotherapy will remain the mainstay of systemic treatment for cancer for the foreseeable future. While considerable progress has occurred, better methods and broader application of supportive care measures are needed to reduce the symptomatic effects of cancer and the associated toxicities associated with cancer treatment. No area of cancer supportive care better illustrates the progress that has resulted from advances in our understanding of cellular and molecular biology, genetic engineering and the development of more effective yet often more toxic cancer treatments than that of the hematopoietic growth factors. This volume will review and integrate the major advances in our understanding of the underlying molecular biology and pharmacology of these agents along with the results of well designed and executed randomized controlled trials of the erythroid stimulating agents, the myeloid growth factors and the new thrombopoietic agents each addressing a major threat associated with bone marrow suppression accompanying cancer treatment. The current clinical utilization of these agents is based on numerous randomized controlled trials and meta-analyses along with evidence-based clinical practice guidelines developed by professional societies guiding their appropriate and cost-effective use in clinical care. 452 pp. Englisch. Codice articolo 9781441970725

Informazioni sul venditore | Contatta il venditore

Compra nuovo
EUR 213,99
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 23,00
Da: Germania a: U.S.A.
Destinazione, tempi e costi
Foto dell'editore

Gary H. Lyman
Editore: Springer (2010)
ISBN 10: 144197072X ISBN 13: 9781441970725
Nuovo Rilegato Quantità: > 20
Print on Demand
Da:
Ria Christie Collections
(Uxbridge, Regno Unito)
Valutazione libreria

Descrizione libro Condizione: New. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book. Codice articolo ria9781441970725_lsuk

Informazioni sul venditore | Contatta il venditore

Compra nuovo
EUR 229,94
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 11,65
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi
Immagini fornite dal venditore

David C. Dale
Editore: Springer US (2010)
ISBN 10: 144197072X ISBN 13: 9781441970725
Nuovo Rilegato Quantità: 1
Da:
AHA-BUCH GmbH
(Einbeck, Germania)
Valutazione libreria

Descrizione libro Buch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - Progress in the treatment of cancer over the past two decades has been rapid with many new and novel therapeutic modalities arriving at an unprecedented pace. Overall cancer mortality rates have actually begun to fall in parallel with progress in the diagnosis and treatment of malignant disease. Despite our advances in the understanding of the biology and molecular genetics of cancer, as well as the availability of an increasing array of effective therapies, cancer treatment today and for the foreseeable future will include the traditional modalities of surgery, radiation therapy and chemotherapy. Myelosuppressive agents with their potential hematopoietic toxicities remain the mainstay of systemic treatment for both metastatic and early stage cancer. The complications of cancer chemotherapy have serious impact on a patient's well being and overall quality of life. Fortunately, advances in cancer treatment have been accompanied by equally impressive progress in the availability of a wide array of supportive care modalities which have greatly enhanced the ability of oncologists to minimize the impact of cancer and its treatment on patient quality of life as well improve delivery of potentially curative cancer treatment. Despite the increasing complexity of modern cancer treatment, it is the obligation of the oncologist as well as the entire cancer care team to be certain that cancer patients receive the optimal supportive care available for their disease and its treatment. Among the most serious and potentially life threatening toxicities of cancer treatment are the hematologic toxicities accompanying myelosuppression including anemia and associated asthenia and fatigue, neutropenia and fever associated with infection in the immunocompromised patient and thrombocytopenia and accompanying risk of bleeding. Special supportive care needs arise in the very elderly care patient that may tax the ability of even the most skilled clinician. Despite the considerable progress that has been made with more effective and safer treatment strategies, myelosuppressive chemotherapy will remain the mainstay of systemic treatment for cancer for the foreseeable future. While considerable progress has occurred, better methods and broader application of supportive care measures are needed to reduce the symptomatic effects of cancer and the associated toxicities associated with cancer treatment. No area of cancer supportive care better illustrates the progress that has resulted from advances in our understanding of cellular and molecular biology, genetic engineering and the development of more effective yet often more toxic cancer treatments than that of the hematopoietic growth factors. This volume will review and integrate the major advances in our understanding of the underlying molecular biology and pharmacology of these agents along with the results of well designed and executed randomized controlled trials of the erythroid stimulating agents, the myeloid growth factors and the new thrombopoietic agents each addressing a major threat associated with bone marrow suppression accompanying cancer treatment. The current clinical utilization of these agents is based on numerous randomized controlled trials and meta-analyses along with evidence-based clinical practice guidelines developed by professional societies guiding their appropriate and cost-effective use in clinical care. Codice articolo 9781441970725

Informazioni sul venditore | Contatta il venditore

Compra nuovo
EUR 216,56
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 32,99
Da: Germania a: U.S.A.
Destinazione, tempi e costi